VKH
NGNE icon

Virtu KCG Holdings’s Neurogene NGNE Stock Holding History

Virtu KCG Holdings’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,640
Closed -$438K – 3668
2016
Q3 		$438K Buy
+1,640
New +$331K 0.01% 1513
2015
Q4 		– Sell
-627
Closed -$176K – 3788
2015
Q3 		$176K Buy
+627
New +$144K ﹤0.01% 2624

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Virtu KCG Holdings's NGNE Position: Q4 2016 in Review

Virtu KCG Holdings sold out of Neurogene (NGNE) in Q4 2016, closing a stake of 1,640 shares — an estimated $438K sold.

Virtu KCG Holdings first reported a position in NGNE in Q3 2015 and held it in 2 quarters. The position peaked at $438K in Q3 2016. 49 funds tracked by Wall St. Rank hold NGNE as of Q4 2016.

  • Virtu KCG Holdings reported no remaining Neurogene position as of Q4 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 1,640 Neurogene shares in Q4 2016, an estimated $438K.
  • Virtu KCG Holdings first reported a position in Neurogene in Q3 2015 and held it in 2 quarters.
  • Virtu KCG Holdings's Neurogene position peaked at $438K in Q3 2016.
  • 49 funds tracked by Wall St. Rank held Neurogene as of Q4 2016.

Based on Virtu KCG Holdings's 13F filing for Q4 2016, filed 10 Feb 2017.